Arecor Therapeutics (AREC)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 43.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 120.00
  • 52 Week Low: 38.00
  • Currency: UK Pounds
  • Shares Issued: 37.76m
  • Volume: 4,377
  • Market Cap: £16.42m

AREC Overview

Arecor is a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying the Group's innovative proprietary formulation technology platform, Arestat™, the Group is developing an internal portfolio of proprietary products, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their partners' therapeutic products, supported by an extensive patent portfolio.

1 Day Chart (19-06-2025)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -211.7% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 3.3 n/a
Pr/Book 3.1  
Latest F'cast
Revenue 10.5% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

AREC Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 1.70 (3.51) (17.00)p n/a n/a n/a n/a 0.0%
31-Dec-21 1.16 (6.95) (27.00)p n/a n/a n/a n/a 0.0%
31-Dec-22 2.40 (10.54) (32.00)p n/a n/a n/a n/a 0.0%
31-Dec-23 4.57 (8.90) (0.28)p n/a n/a n/a n/a 0.0%
31-Dec-24 5.05 (10.62) (0.31)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AREC Company Announcements

Grant of Options and PDMR Dealing 04-Jun-2025 07:00 RNS
Result of AGM 02-Jun-2025 13:32 RNS
Non-Executive Director Board Change 02-Jun-2025 07:00 RNS

AREC ShareCast News

Arecor enters formulation partnership with Skye ... 19-May-2025 ShareCast
Arecor enters collaboration with unnamed global ... 26-Mar-2025 ShareCast
Revenue higher, cash reserves fall at Arecor 03-Feb-2025 ShareCast

Latest AREC Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

AREC Market Data

Currency UK Pounds
Share Price 43.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 120.00
52 Week Low 38.00
Volume 4,377
Shares Issued 37.76m
Market Cap £16.42m

AREC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.5% below the market average46.5% below the market average46.5% below the market average46.5% below the market average46.5% below the market average
13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average
Price Trend
90.24% below the market average90.24% below the market average90.24% below the market average90.24% below the market average90.24% below the market average
69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average
Income Not Available
Growth
43.06% above the market average43.06% above the market average43.06% above the market average43.06% above the market average43.06% above the market average
41.94% above the sector average41.94% above the sector average41.94% above the sector average41.94% above the sector average41.94% above the sector average

AREC Dividends

No dividends found

Trades for 19-Jun-2025

Time Volume / Share Price
14:54 2,346 @ 42.40p
13:46 2,031 @ 41.00p

AREC Key Personnel

CEO Sarah Jennifer Howell
CFO David Ellam

Top of Page